FITC Anti-Integrin beta 3 antibody [VIPL2] (ab269291)
Key features and details
- FITC Mouse monoclonal [VIPL2] to Integrin beta 3
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG1
Overview
-
Product name
FITC Anti-Integrin beta 3 antibody [VIPL2]
See all Integrin beta 3 primary antibodies -
Description
FITC Mouse monoclonal [VIPL2] to Integrin beta 3 -
Host species
Mouse -
Conjugation
FITC. Ex: 493nm, Em: 528nm -
Specificity
ab269291 recognizes an extracellular epitope of CD61.
-
Tested applications
Suitable for: Flow Cytmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Non human primates -
Immunogen
The details of the immunogen for this antibody are not available.
-
Epitope
extracellular -
Positive control
- Flow cyt: Human peripheral blood.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Store In the Dark. -
Storage buffer
pH: 7.4
Preservative: 0.1% Sodium azide
Constituent: PBS -
Concentration information loading...
-
Purity
Size exclusion -
Purification notes
The purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions. The conjugate is purified by size-exclusion chromatography. -
Clonality
Monoclonal -
Clone number
VIPL2 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Alternative Versions
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab269291 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt |
Use 4µl for 106 cells.
Or 100 μL of whole blood. |
Notes |
---|
Flow Cyt
Use 4µl for 106 cells. Or 100 μL of whole blood. |
Target
-
Function
Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
Tissue specificity
Isoform beta-3A and isoform beta-3C are widely expressed. Isoform beta-3A is specifically expressed in osteoblast cells; isoform beta-3C is specifically expressed in prostate and testis. -
Involvement in disease
Defects in ITGB3 are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. It is an autosomal recessive disorder characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb/beta-3 complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the glycoprotein IIb/beta-3 complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT 'variants' have normal or near normal (60-100%) expression of dysfunctional receptors. -
Sequence similarities
Belongs to the integrin beta chain family.
Contains 1 VWFA domain. -
Post-translational
modificationsPhosphorylated on tyrosine residues in response to thrombin-induced platelet aggregation. Probably involved in outside-in signaling. A peptide (AA 740-762) is capable of binding GRB2 only when both Tyr-773 and Tyr-785 are phosphorylated. Phosphorylation of Thr-779 inhibits SHC binding. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 3690 Human
- Omim: 173470 Human
- SwissProt: P05106 Human
- Unigene: 218040 Human
-
Alternative names
- BDPLT16 antibody
- BDPLT2 antibody
- CD 61 antibody
see all
Images
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab269291 has not yet been referenced specifically in any publications.